Cargando…

Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The AKT pathway is often activated in HCC cases, and a longer exposure to tyrosine kinase inhibitors such as sorafenib may lead to over-activation of the AKT pathway, leading to HCC resistance. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurma, Keerthi, Zeybek Kuyucu, Ayca, Roth, Gaël S., Sturm, Nathalie, Mercey-Ressejac, Marion, Abbadessa, Giovanni, Yu, Yi, Lerat, Herve, Marche, Patrice N., Decaens, Thomas, Macek Jilkova, Zuzana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784348/ https://www.ncbi.nlm.nih.gov/pubmed/36555845 http://dx.doi.org/10.3390/ijms232416206

Ejemplares similares

Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
por: Jilkova, Zuzana Macek, et al.
Publicado: (2018)

DEN-Induced Rat Model Reproduces Key Features of Human Hepatocellular Carcinoma
por: Kurma, Keerthi, et al.
Publicado: (2021)

Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Chronic Intermittent Hypoxia Increases Cell Proliferation in Hepatocellular Carcinoma
por: Carreres, Lydie, et al.
Publicado: (2022)

Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment
por: Mroweh, Mariam, et al.
Publicado: (2021)

Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Increased Intrahepatic Expression of Immune Checkpoint Molecules in Autoimmune Liver Disease
por: Macek Jilkova, Zuzana, et al.
Publicado: (2021)

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
por: Carreres, Lydie, et al.
Publicado: (2021)

Sex Differences in Spontaneous Degranulation Activity of Intrahepatic Natural Killer Cells during Chronic Hepatitis B: Association with Estradiol Levels
por: Macek Jilkova, Zuzana, et al.
Publicado: (2017)

Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma
por: Mroweh, Mariam, et al.
Publicado: (2020)

Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma
por: Dumolard, Lucile, et al.
Publicado: (2020)

Circulating IL-13 Is Associated with De Novo Development of HCC in HCV-Infected Patients Responding to Direct-Acting Antivirals
por: Macek Jílková, Zuzana, et al.
Publicado: (2020)

Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation
por: Dumolard, Lucile, et al.
Publicado: (2023)

Reply to Comment on “Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges” Cancers 2019, 11, 1554
por: Macek Jilkova, Zuzana, et al.
Publicado: (2020)

Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Functions of Liver Natural Killer Cells Are Dependent on the Severity of Liver Inflammation and Fibrosis in Chronic Hepatitis C
por: Fugier, Emilie, et al.
Publicado: (2014)

Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C
por: Malov, S.I., et al.
Publicado: (2021)

GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition
por: Bestion, Eloïne, et al.
Publicado: (2020)

Gamma delta T cells in hepatocellular carcinoma: Sunrise of new therapy based on Vδ2 T cells?
por: Macek Jilkova, Zuzana
Publicado: (2022)

Mechanobiology and survival strategies of circulating tumor cells: a process towards the invasive and metastatic phenotype
por: Kurma, Keerthi, et al.
Publicado: (2023)

Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib
por: Coriat, Romain, et al.
Publicado: (2011)

Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line
por: Roth, Gael S., et al.
Publicado: (2020)

The Chicken Embryo Model: A Novel and Relevant Model for Immune-Based Studies
por: Garcia, Paul, et al.
Publicado: (2021)

Combining Crocin and Sorafenib Improves Their Tumor-Inhibiting Effects in a Rat Model of Diethylnitrosamine-Induced Cirrhotic-Hepatocellular Carcinoma
por: Awad, Basma, et al.
Publicado: (2023)

GNS561, a New Autophagy Inhibitor Active against Cancer Stem Cells in Hepatocellular Carcinoma and Hepatic Metastasis from Colorectal Cancer
por: Brun, Sonia, et al.
Publicado: (2021)

Impact of sorafenib on epidural fibrosis: An immunohistochemical study
por: Tanriverdi, Osman, et al.
Publicado: (2018)

GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions
por: Brun, Sonia, et al.
Publicado: (2021)

Prognosis of cirrhotic patients admitted to the general ICU
por: Piton, Gaël, et al.
Publicado: (2016)

The inhibition of fat cell proliferation by n-3 fatty acids in dietary obese mice
por: Hensler, Michal, et al.
Publicado: (2011)

Cirrhotic cardiomyopathy: An independent prognostic factor for cirrhotic patients
por: Lee, Yun Bin, et al.
Publicado: (2018)

Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
por: Roth, Gaël Stéphane, et al.
Publicado: (2020)

Cirrhotic cardiomyopathy
por: Baik, Soon Koo, et al.
Publicado: (2007)

Cirrhotic cardiomyopathy
por: Grancea-Iancu, VLM
Publicado: (2014)

Non-Traumatic Intramuscular Hip Hematoma in a Cirrhotic Patient With Hepatocellular Carcinoma and Portal Vein Thrombosis Treated With Sorafenib and Low Molecular Weight Heparin
por: Sotiropoulos, Christos, et al.
Publicado: (2021)

The envelope of human endogenous retrovirus in neuro-inflammation
por: Dougier, Hei-Lanne, et al.
Publicado: (2009)

Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease
por: Hartl, Lukas, et al.
Publicado: (2021)

CCM proteins control endothelial β1 integrin dependent response to shear stress
por: Macek Jilkova, Zuzana, et al.
Publicado: (2014)

Laparoscopic Cholecystectomy in Cirrhotics
por: Machado, Norman Oneil
Publicado: (2012)

VRE in cirrhotic patients
por: Barger, Melissa, et al.
Publicado: (2019)

Anticoagulation in the cirrhotic patient
por: Turco, Laura, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ukjc7n0ofckb4keb4nnoglqg28